Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions.

ABSTRACT:

Background

Cytotoxic T lymphocyte-mediated (CTL-mediated) severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), are rare but life-threatening adverse reactions commonly induced by drugs. Although high levels of CTL-associated cytokines, chemokines, or cytotoxic proteins, including TNF-α and granulysin, were observed in SJS-TEN patients in recent studies, the optimal treatment for these diseases remains controversial. We aimed to evaluate the efficacy, safety, and therapeutic mechanism of a TNF-α antagonist in CTL-mediated SCARs.

Methods

We enrolled 96 patients with SJS-TEN in a randomized trial to compare the effects of the TNF-α antagonist etanercept versus traditional corticosteroids.

Results

Etane

SUBMITTER: Wang CW 

PROVIDER: S-EPMC5824923 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature